561 related articles for article (PubMed ID: 26811670)
1. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
2. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
3. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
4. Ixazomib - the first oral proteasome inhibitor.
Xie J; Wan N; Liang Z; Zhang T; Jiang J
Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
[TBL] [Abstract][Full Text] [Related]
5. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
Ri M
Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
[TBL] [Abstract][Full Text] [Related]
6. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitors for the treatment of multiple myeloma.
Scalzulli E; Grammatico S; Vozella F; Petrucci MT
Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
Fogli S; Galimberti S; Gori V; Del Re M; Danesi R
Pharmacol Res; 2021 May; 167():105537. PubMed ID: 33684510
[TBL] [Abstract][Full Text] [Related]
9. Oral ixazomib maintenance therapy in multiple myeloma.
Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors: structure and function.
Nunes AT; Annunziata CM
Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
[TBL] [Abstract][Full Text] [Related]
11. Safety of ixazomib for the treatment of multiple myeloma.
Bonnet A; Moreau P
Expert Opin Drug Saf; 2017 Aug; 16(8):973-980. PubMed ID: 28661711
[TBL] [Abstract][Full Text] [Related]
12. Ixazomib: First Global Approval.
Shirley M
Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
[TBL] [Abstract][Full Text] [Related]
13. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
[TBL] [Abstract][Full Text] [Related]
14. Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.
Gupta N; Hanley MJ; Diderichsen PM; Yang H; Ke A; Teng Z; Labotka R; Berg D; Patel C; Liu G; van de Velde H; Venkatakrishnan K
Clin Pharmacol Ther; 2019 Feb; 105(2):376-387. PubMed ID: 29446068
[TBL] [Abstract][Full Text] [Related]
15. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
16. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
Al-Salama ZT; Garnock-Jones KP; Scott LJ
Target Oncol; 2017 Aug; 12(4):535-542. PubMed ID: 28660423
[TBL] [Abstract][Full Text] [Related]
17. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Manda S; Yimer HA; Noga SJ; Girnius S; Yasenchak CA; Charu V; Lyons R; Aiello J; Bogard K; Ferrari RH; Cherepanov D; Demers B; Lu V; Whidden P; Kambhampati S; Birhiray RE; Jhangiani HS; Boccia R; Rifkin RM
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e910-e925. PubMed ID: 32912820
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Richardson PG; Baz R; Wang M; Jakubowiak AJ; Laubach JP; Harvey RD; Talpaz M; Berg D; Liu G; Yu J; Gupta N; Di Bacco A; Hui AM; Lonial S
Blood; 2014 Aug; 124(7):1038-46. PubMed ID: 24920586
[TBL] [Abstract][Full Text] [Related]
20. Ixazomib for the treatment of multiple myeloma.
Richardson PG; Zweegman S; O'Donnell EK; Laubach JP; Raje N; Voorhees P; Ferrari RH; Skacel T; Kumar SK; Lonial S
Expert Opin Pharmacother; 2018 Dec; 19(17):1949-1968. PubMed ID: 30422008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]